Table 2

Neovascularisation status in the intravitreal pegaptanib (IVP) and panretinal laser photocoagulation (PRP)-treated eyes

Neovascularisation statusWeek 3Week 6Week 12Week 18Week 24Week 30Week 36
IVP (N = 10)PRP (N = 9)IVP (N = 10)PRP (N = 9)IVP = 10PRP = 9IVP = 10PRP = 8IVP = 9PRP = 8IVP = 9PRP = 8IVP = 8PRP = 8
Active0 (0%)7 (78%)0 (0%)5 (56%)0 (0%)3 (33%)0 (0%)2 (25%)0 (0%)3 (38%)0 (0%)4 (50%)0 (0%)4 (50%)
Partial1 (10%)0 (0%)1 (10%)2 (22%)0 (0%)3 (33%)0 (0%)4 (50%)0 (0%)3 (38%)0 (0%)2 (25%)0 (0%)2 (25%)
Regressed9 (90%)2 (22%)9 (90%)2 (22%)10 (100%)3 (33%)10 (100%)2 (25%)9 (100%)2 (25%)9 (100%)2 (25%)8 (100%)2 (25%)
  • N, number of patients.